ISPOR PUBLISHES TASK FORCE REPORT #2 ON MULTIPLE CRITERIA DECISION ANALYSIS

Published Apr 5, 2016

Second Report Published in March/April Issue of Value in Health

Princeton, NJ—April 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published a new Task Force Report, “Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force, ” in the March/April 2016 issue of Value in Health.  Many health care decisions are complex and require consideration of multiple, often conflicting objectives. They involve trade-offs that decision makers find challenging or on which they disagree. For instance, regulators often have to assess whether the benefits of a drug are sufficient to accept its safety risks. Lead author Kevin Marsh stated, “Decision makers, whether they are individuals, payers, or health ministries, often have difficulty processing and systematically evaluating potential treatment options and the numerous disparate factors impacting them. This set of techniques known as multiple criteria decision analysis (MCDA) can significantly improve the quality of complicated health care decisions.” This second MCDA Task Force Report builds on the foundational Report #1, “Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force,” published in the January/February 2016 issue of Value in Health. Co-author Maarten IJzerman explained, “While many MCDA methods exist, there is currently insufficient guidance on how to choose the right technique for a specific health care issue. The good practice guidelines provide an overview of the available MCDA methods and the principles to apply in choosing an appropriate method for a particular problem or decision.” The Task Force also developed a valuable checklist, the ISPOR MCDA Good Practice Guidelines Checklist, that outlines the steps for implementing MCDA. Finally, the capacity of MCDA to incorporate patients’ preferences on benefits and trade-offs of treatment options is an important benefit to all stakeholders.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×